Advanced

Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.

Rathkopf, Dana E; Larson, Steven M; Anand, Aseem LU ; Morris, Michael J; Slovin, Susan F; Shaffer, David R; Heller, Glenn; Carver, Brett; Rosen, Neal and Scher, Howard I (2015) In Cancer 121(21). p.3853-3861
Abstract
The effects of mammalian target of rapamycin (mTOR) inhibition are limited by feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin homolog-null tumors. Thus, this study tested the combination of mTOR inhibition (everolimus) and epidermal growth factor receptor inhibition (gefitinib) in castration-resistant prostate cancer (CRPC).
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cancer
volume
121
issue
21
pages
3853 - 3861
publisher
John Wiley & Sons
external identifiers
  • pmid:26178426
  • wos:000363262100016
  • scopus:84944768819
ISSN
1097-0142
DOI
10.1002/cncr.29578
language
English
LU publication?
yes
id
4c5f3dbc-1bd0-459e-89d1-c90787e1708d (old id 7749443)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26178426?dopt=Abstract
date added to LUP
2015-08-09 00:17:33
date last changed
2017-10-01 03:00:19
@article{4c5f3dbc-1bd0-459e-89d1-c90787e1708d,
  abstract     = {The effects of mammalian target of rapamycin (mTOR) inhibition are limited by feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin homolog-null tumors. Thus, this study tested the combination of mTOR inhibition (everolimus) and epidermal growth factor receptor inhibition (gefitinib) in castration-resistant prostate cancer (CRPC).},
  author       = {Rathkopf, Dana E and Larson, Steven M and Anand, Aseem and Morris, Michael J and Slovin, Susan F and Shaffer, David R and Heller, Glenn and Carver, Brett and Rosen, Neal and Scher, Howard I},
  issn         = {1097-0142},
  language     = {eng},
  number       = {21},
  pages        = {3853--3861},
  publisher    = {John Wiley & Sons},
  series       = {Cancer},
  title        = {Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.},
  url          = {http://dx.doi.org/10.1002/cncr.29578},
  volume       = {121},
  year         = {2015},
}